Fundz
Funding, M&A, exec moves and hiring — every signal, the moment it breaks.See plans →

Alzamend Neuro secures $7.5 million in initial tranche of Convertible Preferred Stock from Ault Lending as part of a $25 million agreement to support development efforts.

PUBLIC · ALZNAug 04, 2026•3 days ago

Amount Raised

$7.5 Million

Round Type

Series D

AtlantaBiotechnologyHealth CareScience And Engineering

Investors

Ault Lending, Llc

Description

Alzamend Neuro has announced the initial closing of a Securities Purchase Agreement with Ault Lending. The agreement allows Ault Lending to purchase up to $25 million of the company's Series D Convertible Preferred Stock. Ault Lending has closed on the initial tranche of $7.5 million. The proceeds will be used for general working capital and corporate purposes.

Company Information

Company

Alzamend Neuro

Location

Atlanta, Georgia, United States

About

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.

Related People

Suggested for you
5 contacts
Verified contactsJames, Deputy General Counsel and Vice Preside… hidden hidden
Predictive Intelligence
Strategic

ML-powered predictions for Alzamend Neuro's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Alzamend Neuro? See every signal — funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan